Detalles de la búsqueda
1.
Disease progression model using the integrated Alzheimer's Disease Rating Scale.
Alzheimers Dement
; 19(6): 2253-2264, 2023 06.
Artículo
Inglés
| MEDLINE | ID: mdl-36450003
2.
Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Br J Clin Pharmacol
; 88(3): 1074-1086, 2022 03.
Artículo
Inglés
| MEDLINE | ID: mdl-34378230
3.
Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.
Diabetes Obes Metab
; 19(1): 33-39, 2017 01.
Artículo
Inglés
| MEDLINE | ID: mdl-27484286
4.
Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies.
Clin Pharmacokinet
; 62(10): 1479-1491, 2023 10.
Artículo
Inglés
| MEDLINE | ID: mdl-37610533
5.
Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease.
Clin Pharmacol Ther
; 113(6): 1258-1267, 2023 06.
Artículo
Inglés
| MEDLINE | ID: mdl-36805552
6.
Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease.
Alzheimers Dement (N Y)
; 9(2): e12404, 2023.
Artículo
Inglés
| MEDLINE | ID: mdl-37388759
7.
A Euglycemic Glucose Clamp Study to Evaluate the Bioavailability of LY2963016 Relative to Insulin Glargine in Healthy Chinese Subjects.
Clin Pharmacol Drug Dev
; 10(12): 1452-1459, 2021 12.
Artículo
Inglés
| MEDLINE | ID: mdl-34410042
8.
Donanemab (LY3002813) dose-escalation study in Alzheimer's disease.
Alzheimers Dement (N Y)
; 7(1): e12112, 2021.
Artículo
Inglés
| MEDLINE | ID: mdl-33614890
9.
Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis.
J Invest Dermatol
; 138(10): 2168-2173, 2018 10.
Artículo
Inglés
| MEDLINE | ID: mdl-29751001
10.
Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis.
J Clin Pharmacol
; 58(11): 1489-1500, 2018 11.
Artículo
Inglés
| MEDLINE | ID: mdl-29878382
11.
Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.
CPT Pharmacometrics Syst Pharmacol
; 6(12): 804-813, 2017 12.
Artículo
Inglés
| MEDLINE | ID: mdl-28891251
12.
LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels.
Clin Pharmacol Drug Dev
; 6(6): 556-563, 2017 Nov.
Artículo
Inglés
| MEDLINE | ID: mdl-28940840
13.
Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies.
Diabetes Care
; 38(12): 2226-33, 2015 Dec.
Artículo
Inglés
| MEDLINE | ID: mdl-26307603
Resultados
1 -
13
de 13
1
Próxima >
>>